Relationship between metalloprotease expression in tumour and stromal cells and aggressive behaviour in prostate carcinoma: Simultaneous high-throughput study of multiple metalloproteases and their inhibitors using tissue array analysis of radical prostatectomy samples

References

• Kirby RS, Partin A, Parsons JK, Feneley M. Treatment methods for early and advanced prostate cancer. New York: Informa HealthCare; 2008. p 107–14.
   Google Scholar
• Hughes C, Murphy A, Martin C, Sheils O, O'Leary J. Molecular pathology of prostate cancer. J Clin Pathol 2005;58:673–84.
   PubMed Web of Science ®Google Scholar
• Demers M, Couillard J, Belanger S, St-Pierre Y. New roles for matrix metalloproteinases in metastasis. Crit Rev Immunol 2005;25:493–523.
   PubMed Web of Science ®Google Scholar
• Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 2001; 114:111–18.
   PubMed Web of Science ®Google Scholar
• Cunya GR, Hayward SW, Wang YZ, Ricke WA. Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer 2003;107:1–10.
   PubMed Web of Science ®Google Scholar
• Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 2007;51:1202–16.
   PubMed Web of Science ®Google Scholar
• Gross-Goupil M, Massard C, Fizazi K. Integrating molecular oncology into therapeutic strategies for prostate cancer. Eur Urol Suppl 2009;8:114–19.
   Web of Science ®Google Scholar
• Wilson TJ, Singh RK. Proteases as modulators of tumour–stromal interaction: primary tumours to bone metastases. Biochim Biophys Acta 2008;1785:85–95.
   PubMed Web of Science ®Google Scholar
• Brehmer B, Biesterfeld S, Jakse G. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue. Prostate Cancer Prostatic Dis 2003; 6:217–22.
   PubMed Web of Science ®Google Scholar
• Pang ST, Flores-Morales A, Skoog L, Chuan YC, Nordstedt G, Pousette A. Regulation of matrix metalloproteinase 13 expression by androgen in prostate cancer. Oncol Rep 2004;11:1187–92.
   PubMed Web of Science ®Google Scholar
• Zhang L, Shi J, Feng J, Klocker H, Lee C, Zhang J. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. Prostate Cancer Prostatic Dis 2004;7:327–32.
   PubMed Web of Science ®Google Scholar
• Cao J, Chiarelli C, Richman O, Zarrabi K, Kozarekar P, Zucker S. Membrane type 1 matrix metalloproteinase induces epithelial-to-mesenchymal transition in prostate cancer. J Biol Chem 2008;283:6232–40.
   PubMed Web of Science ®Google Scholar
• Trudel D, Fradet Y, Meyer F, Harel F, Tetu B. Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. Cancer Res 2003;63:8511–15.
   PubMed Web of Science ®Google Scholar
• Flemming ID, Cooper IS, Hemson DE. The 1992 TNM classification. American Joint Committtee on Cancer Staging Manual, 5th ed. Philadelphia, PA: JB Lippincott; 1997. p 219–22.
   Google Scholar
• Whitmore W. Hormone therapy in prostatic cancer. Human Pathol 1956;21:273–9.
   Google Scholar
• Parker RL, Huntsman DG, Lesack DW, Cupples JB, Grant DR, Akbari M, Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol 2002;117:723–8.
   PubMed Web of Science ®Google Scholar
• Liotta LA, Kohn EC. The microenvironment of the tumour–host interface. Nature 2001;411:375–9.
   PubMed Web of Science ®Google Scholar
• Hara T, Miyazaki H, Lee A, Tran CP, Reiter RE. Androgen receptor and invasion in prostate cancer. Cancer Res 2008;68:1128–35.
   PubMed Web of Science ®Google Scholar
• Mylona E, Kapranou A, Mavrommatis J, Markaki S, Keramopoulos A, Nakopoulou L. The multifunctional role of the immunohistochemical expression of MMP-7 in invasive breast cancer. APMIS 2005, 113:246–55.
   PubMed Web of Science ®Google Scholar
• Abdel-Ghany M, Cheng HC, Elble RC, Pauli BU. The breast cancer beta 4 integrin and endothelial human CLCA2 mediate lung metastasis. J Biol Chem 2001;276:25438–46.
   PubMed Web of Science ®Google Scholar
• Davies G, Jiang WG, Mason MD. Matrilysin mediates extracellular cleavage of E-cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cell–cell dissociation and in vitro invasion. Clin Cancer Res 2001;7:3289–97.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002;21:2245–52.
   PubMed Web of Science ®Google Scholar
• Wang F, Reierstad S, Fishman DA. Matrilysin over-expression in MCF-7 cells enhances cellular invasiveness and pro-gelatinase activation. Cancer Lett 2006;236:292–301.
   PubMed Web of Science ®Google Scholar
• Vizoso FJ, Gonzalez LO, Corte MD, Rodriguez JC, Vazquez J, Lamelas ML, Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer 2007;96:903–11.
   PubMed Web of Science ®Google Scholar
• Freije JM, Diez-Itza I, Balbin M, Sanchez LM, Blasco R, Tolivia J, Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 1994;269:16766–73.
   PubMed Web of Science ®Google Scholar
• Knauper V, Cowell S, Smith B, Lopez-Otin C, O'shea M, Morris H, The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J Biol Chem 1997;272:7608–16.
   PubMed Web of Science ®Google Scholar
• Chesler L, Golde DW, Bersch N, Johnson MD. Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1. Blood 1995;86:4506–15.
   PubMed Web of Science ®Google Scholar
• Luparello C, Avanzato G, Carella C, Pucci-Minafra I. Tissue inhibitor of metalloprotease (TIMP)-1 and proliferative behaviour of clonal breast cancer cells. Breast Cancer Res Treat 1999;54:235–44.
   PubMed Web of Science ®Google Scholar
• Wurtz SO, Schrohl AS, Sorensen NM, Lademann U, Christensen IJ, Mouridsen H, Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocr Relat Cancer 2005;12:215–27.
   PubMed Web of Science ®Google Scholar
• Yoshiji H, Harris SR, Raso E, Gomez DE, Lindsay CK, Shibuya M, Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int J Cancer 1998;75:81–7.
   PubMed Web of Science ®Google Scholar